Dianthus Therapeutics

Historical price data

Dianthus Therapeutics is a clinical-stage biotech company focused on developing precision monoclonal antibody therapeutics for autoimmune diseases. Its core strategy is the selective inhibition of the classical complement pathway via its lead candidate, DNTH103, which targets C1s. The company went public in 2024, securing capital to advance its pipeline through clinical trials. Its mission is to address unmet needs in autoimmune care by developing therapies with potentially superior safety and tolerability compared to broad immunosuppressants.

Precision monoclonal antibody platform designed to selectively inhibit the classical complement pathway by targeting the C1s serine protease, aiming to preserve beneficial immune functions of the alternative and lectin pathways.

Dianthus competes with broad-spectrum complement C5 inhibitors (e.g., Soliris, Ultomiris), other classical pathway modulators like FcRn blockers (Vyvgart), and anti-C1q therapies. Its competitive edge hinges on demonstrating that selective C1s inhibition provides meaningful efficacy with a superior safety and convenience profile.